The development of COVID-19 vaccines around the world has been in the spotlight since the start of the pandemic. Various research institutes and pharmaceutical companies are working hard to develop effective vaccines. To date, several vaccines have received approval from health authorities in their respective countries. mRNA vaccines, such as Pfizer-BioNTech and Moderna, have shown high efficacy in preventing COVID-19 infection. Both vaccines use mRNA technology which instructs the body’s cells to produce the virus’ spike protein, stimulating an immune response. Clinical trial results show efficiency of more than 90%, making it the first choice in immunization programs. Meanwhile, inactivated virus-based vaccines such as Sinovac and Sinopharm have also received attention. This vaccine uses the SARS-CoV-2 virus which has been inactivated, so it is safe to use. Studies show that the vaccine has an efficacy rate ranging from 50% to 85% depending on the population and circulating virus variants. The AstraZeneca vaccine, which uses an adenovirus viral vector, is one of the most widely used vaccines in low- and middle-income countries. With low production costs and good effectiveness, this vaccine plays an important role in global vaccination programs. However, reports of side effects such as blood clots have raised concerns among the public. Apart from that, the Novavax vaccine which is based on subunit proteins has also provided an additional alternative. This vaccine uses an engineered viral spike protein to trigger an immune response. Although not yet as numerous as mRNA or adenovirus vaccines, early data shows promising results. Countries such as India have carried out mass vaccination programs with domestic vaccines, such as Covaxin and Covishield, which are versions of the AstraZeneca vaccine. Indonesia’s and Brazil’s experiences with vaccination show similar distribution challenges, especially in remote areas. Meanwhile, vaccine development does not just stop with the currently available vaccines. Several institutions are experimenting with vaccine boosters to increase body immunity, especially against new variants such as Delta and Omicron. Continued research is essential to overcome virus mutations and improve vaccine effectiveness. Therefore, international cooperation in vaccine distribution is also very necessary. The COVAX initiative focuses on equitable distribution of vaccines to disadvantaged countries to ensure global coverage. As vaccination increases, hopes of achieving herd immunity are moving closer to reality. It is also important to consider the role of the community in the vaccination campaign. Education and understanding about vaccine safety are key to increasing participation. Fake news about vaccines often creates unfounded fear among the public. With all these developments, transparency in vaccine information has become crucial. Health authorities around the world are expected to provide accurate and easy-to-understand information to support individuals in making decisions regarding vaccination. The COVID-19 vaccine is an important step towards recovery and normal life.
